| Company Name: |
Lynnchem |
| Tel: |
86-(0)29-85992781 17792393971 |
| Email: |
info@lynnchem.com |
CAERULOMYCIN A manufacturers
- CAERULOMYCIN A
-
-
2026-07-10
- CAS:21802-37-9
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
- Caerulomycin A
-
- $148.00
-
2026-05-11
- CAS:21802-37-9
- Purity: 99.28%
- Supply Ability: 10g
- Caerulomycin A
-
- $148.00
-
2026-04-21
- CAS:21802-37-9
- Purity: 99.28%
- Supply Ability: 10g
|
| | CAERULOMYCIN A Basic information |
| Product Name: | CAERULOMYCIN A | | Synonyms: | AERULOMYCIN A;(E)-4-Methoxy-[2,2'-bipyridine]-6-carbaldehyde oxime;4-Methoxy-2,2'-bipyridine-6-carbaldehyde (E)-oxime;(2,2'-Bipyridine)-6-carboxaldehyde, 4-methoxy-, oxime, (E)-;CeruloMycin, CaeruloMycin A;CAERULOMYCIN;CAERULOMYCIN A;Carulomycin A | | CAS: | 21802-37-9 | | MF: | C12H11N3O2 | | MW: | 229.23 | | EINECS: | | | Product Categories: | Antibiotic | | Mol File: | 21802-37-9.mol |  |
| | CAERULOMYCIN A Chemical Properties |
| Melting point | 173 °C | | Boiling point | 420.0±45.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to 10 mg/ml). | | pka | 9.89±0.50(Predicted) | | form | solid | | color | White | | biological source | Streptomyces caeruleus | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. | | InChI | 1S/C12H11N3O2/c1-17-10-6-9(8-14-16)15-12(7-10)11-4-2-3-5-13-11/h2-8,16H,1H3/b14-8+ | | InChIKey | JCTRJRHLGOKMCF-RIYZIHGNSA-N | | SMILES | COc1cc(\C=N\O)nc(c1)-c2ccccn2 |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 | | HS Code | 2933399990 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral
Eye Irrit. 2
Skin Irrit. 2 |
| | CAERULOMYCIN A Usage And Synthesis |
| Description | Caerulomycin A (21802-37-9) chemically novel and potent immunosuppressive agent. Suppresses T cell activation and IFN7gamma; secretionin vitroandin vivo.1 Caerulomycin A induces expansion of regulatory T cells by via interfering with IFNγ -induced STAT1 signaling.2 | | Uses | Caerulomycin is a rare and unusual antibiotic containing a core 2, 2’-bispyridyl with an oxime substituent, produced by a strain of Streptomyces caeruleus isolated in Canada in 1959. Caerulomycin is active against fungi and some protozoans, and is weakly active against bacteria. While its discovery has stimulated some synthetic effort, little is known about the mode and spectrum of action of caerulomycin. | | Uses | Caerulomycin A is a pyridine derived antiobiotic with a broad spectrum of bioactivity. | | Definition | ChEBI: Caerulomycin A is a pyridine alkaloid that is 2,2'-bipyridine substituted by a methoxy group at position 4 and a (E)-(hydroxyimino)methyl group at position 6. Isolated from the marine-derived actinomycete Actinoalloteichus cyanogriseus, it exhibits antineoplastic activity. It has a role as an antineoplastic agent, a marine metabolite and a bacterial metabolite. It is an aldoxime, an aromatic ether, a member of bipyridines and a pyridine alkaloid. It derives from a hydride of a 2,2'-bipyridine. | | References | [1] ARVIND K SINGLA. Caerulomycin A suppresses immunity by inhibiting T cell activity.[J]. ACS Applied Bio Materials, 2014: e107051. DOI:10.1371/journal.pone.0107051
[2] RAMA KRISHNA GURRAM. Caerulomycin A enhances transforming growth factor-β (TGF-β)-Smad3 protein signaling by suppressing interferon-γ (IFN-γ)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs).[J]. The Journal of Biological Chemistry, 2014: 17515-17528. DOI:10.1074/jbc.m113.545871 |
| | CAERULOMYCIN A Preparation Products And Raw materials |
|